HTL0014242
Phase 1- Indications
- Neurological disorders, Anxiety
Company intelligence / Profile preview
Heptares has built a pipeline of novel medicines targeting historically undruggable or challenging GPCRs using its proprietary StaR® technology. The company has advanced candidates into clinical development for CNS disorders and immuno-oncology. It has established major partnerships with leading pharmaceutical companies to further develop and commercialize its discoveries.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Heptares Therapeutics.